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Aim. We intend to characterize the new peptide-specific antibodies against the isoform 2 of translation elongation
factor 1A (eEF1A2) and determine its presence in the postoperative samples of human breast, lung and stomach
tumor tissues.Methods. The analysis of antibody specificity was performed by enzyme-linked immunosorbent as-
say, immunoblotting and immunohistochemistry. Immunoblotting and immunohistochemistry were used for the
determination of the eEF1A2 in the human tumor samples, as well as in the samples of normal tissues surroun-
ding tumors. Results. The antibodies obtained against the eEF1A2 specifically recognized this protein in the cell
extracts and histological sections and did not cross-react with the elongation factor 1A isoform 1. eEF1A2 was
revealed in the postoperative samples of breast, lung and stomach tumors as well as in the putative normal tis-
sues surrounding tumors. Conclusions. The antibodies obtained against eEF1A2 are highly specific for the anti-
gen and can be used for the immunological studies of tumors.
Keywords: eEF1A2, anti-peptide antibodies, immunoblotting, immunohistochemistry.
Introduction. Eukaryotic translation elongation factor
1A (eEF1A) provides the process of peptide chain elon-
gation in a cell via delivering the aminoacylated tRNA
to the A-site of the ribosome [1]. Moreover, eEF1A is
also involved in the functioning of other cellular proces-
ses not directly related to the translation [2–5].
In vertebrates, unlike other organisms, two isoforms
of translation elongation factor 1A, named eEF1A1 and
eEF1A2, are present. Despite the fact that these isoforms
are encoded by different genes, they share 92 % of iden-
tity of their amino acid sequences [6]. Interestingly, the
expression of both isoforms in an organism is mutually
exclusive. The presence of eEF1A2 is usually limited to
neurons, muscle cells and cardiomyocytes. However,
during carcinogenesis this isoform appears in those tis-
sues, where it is absent in the normal state [7–9]; this
fact may point to the eEF1A2 oncogenic properties [7,
8]. Until now the reason of mutually exclusive distribu-
tion of eEF1A isoforms in an organism and the mecha-
nism of induction of eEF1A2 expression in tumors re-
main unknown. The appearance of eEF1A2 in some tis-
sues after their malignant transformations suggests the
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existence of a specific signaling pathway, which may
«turn on» the expression of certain set of genes inclu-
ding EEF1A2. Recently, a considerable evidence for the
microRNA-mediated regulation of the EEF1A2 expres-
sion has been obtained [10].
Since eEF1A1 and eEF1A2 isoforms differ in phy-
sical and chemical properties [11, 12] and differently in-
teract with somee signaling proteins [13], the non-cano-
nical functions of these isoforms in a cell, particularly
those associated with carcinogenesis, may also vary.
For example, certain studies demonstrated the anti-
apoptotic properties of eEF1A2, whereas eEF1A1, by
contrast, was considered to be the pro-apoptotic protein
[14, 15], although some authors also observed the anti-
apoptotic effect of the latter [16, 17].
The appearance of eEF1A2 in the samples of the
breast [8, 18], pancreas [19], ovarian [20–22], lung [9,
23], liver [24] and stomach [25] cancer suggests a role
of this protein in tumorigenesis, but its exact function
in cancer cells remains unknown. It should be noted that
the eEF1A2 expression in tumors was determined in
most cases either at the mRNA level or with the help of
commercial antibodies, which were not checked for the
absence of cross-reactivity with eEF1A1. Only one la-
boratory in the world reported the use of eEF1A2-
specific antibodies for the location of this eEF1A iso-
form in tissues [8, 20]. At present, this antibody prepa-
ration is not commercially available.
In order to study the eEF1A2 function in tumorige-
nesis one must have a tool to detect this protein in the
cells and cell extracts. Currently, a monospecific anti-
body preparation is the only appropriate tool that can be
made. Recently, we have shown that mouse immuniza-
tion with one of the eEF1A2 fragments conjugated to bo-
vine serum albumin (BSA) led to the generation of anti-
bodies that specifically interactedwith purified eEF1A2,
but not with eEF1A1 [26]. In this paper we characterize
the peptide-specific antibodies obtained after immuni-
zation of goat with the abovementioned peptide conju-
gated to hemocyanin and ovalbumin. The specificity of
the antibody preparation was tested with both purified
isoforms of translation elongation factor 1A as well as at
the histological sections and cell extracts that contained
only one isoform. Using this antibodies, we also detec-
ted eEF1A2 in the human postoperative malignant tis-
sue samples of several organs.
Materials and methods. Synthesis of antigenic
peptide KSDPPQEAAQFTSQ, its purification and con-
jugation to keyhole limpet hemocyanin and ovalbumin
were performed as described in [26]. Conjugates were
characterized by determining the number of peptide co-
pies per molecule of conjugate by MALDI-TOF mass
spectrometry [26].
Immunization of goat was performed as follows.
The first injection (day 0) was made with 1 mg peptide-
hemocyanin conjugate in 2 ml of 1:1 (v/v) mixture of
Complete Freund's Adjuvant (CFA) and 0.9 % NaCl
water solution. The second and third injections (14th
and 28th days) were made with 1 mg peptide-hemocya-
nin conjugate in 2ml of 1:1 (v/v) mixture of Incomplete
Freund's Adjuvant (IFA) and 0.9 % NaCl water solu-
tion. All injections were made subcutaneously (s. c.).
The first test-bleeding (20 ml) was done on 35th day,
and the serum antibody titer was determined by ELISA
using native and denatured eEF1A2 protein. The fourth
and fifth s. c. injections (42th and 56th days) were done
with 1 mg peptide-ovalbumin conjugate in 2 ml of 1:1
(v/v) mixture of CFA and 0.9 % NaCl water solution.
One week after the fifth injection the preparative blee-
ding (100 ml) was performed and the serum was obtai-
ned. IgGs were further purified by ammonium sulfate
precipitation (40% saturation) and after dialysis on Blue
DEAE-Affi-gel column according to the manufactu-
rer's recommendations («Bio-Rad Laboratories», USA).
Antibodies were finally purified on an affinity column
with immobilized peptide. The affinity matrix was made
by ligating the antigenic peptide to N-hydroxysulfo-
succinimide-activated Affi-gel 15 resin according to
the manufacturer's recommendations («Bio-Rad Labo-
ratories»). 4 mmoles of peptide were immobilized onto
1 ml of Affi-gel matrix. The IgG fraction obtained after
Blue DEAE-Affi-gel was loaded directly on an affinity
column, which was pre-equilibrated with a sample buf-
fer containing 20 mM Tris-HCl, pH 8.0, 25 mM NaCl
and 0.02 % (w/v) NaN3. The column was extensively
washed by the same sample buffer to remove nonspeci-
fically adsorbed proteins. The peptide-specific antibo-
dies were eluted from the column by 0.1 M glycine-
HCl, pH 2.4 buffer containing 0.025%NaN3. The eluate
fractions (7 ml) were collected into tubes with 467l of
1 M Tris-HCl buffer, pH 8.5 that were periodically stir-
red to reach a neutral pH value. Then the fractions were
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concentrated using Vivaspin 6 PES concentrators (30
kDa pore size, «Sartorius», Germany) to 0.5 ml. After
that, the antibody fractions were diluted by 5 ml PBS,
followed by concentrating in the same concentrator tu-
be. This procedure was repeated three times in order to
replace the previous sample buffer solution with PBS.
After the last round of concentration the antibody titers
and protein concentrations were measured as described
in [26]. The fractions with the highest titer were diluted
with glycerol up to 50 % (v/v) and stored at –20 °C.
Individual eEF1A1 and eEF1A2 proteins from rab-
bit tissueswere purified as described previously [12, 27].
Samples of normal rabbit tissues, including muscle,
heart (tissues containing eEF1A2), liver and lung (tis-
sues containing eEF1A1) and postoperative tissue
samples of lung, kidney, breast, stomach malignant tu-
mors as well as respective normal tissues surrounding
tumors were employed in immunohistochemical stu-
dies of eEF1A2 localization. The samples of normal tis-
sues were taken after euthanasia of an animal.
Paraffin blocks of postoperative samples of human
malignant tumors, control tissues and normal rabbit tis-
sues were prepared according to a standard histological
technique.
Paraffin blockswere sliced by themicrotome («Mic-
rom» HM430, «Karl Zeiss», Germany). Immunohisto-
chemical study of tissue samples was carried out accor-
ding to the protocol described previously [28]; the man-
datory control staining of tissue sections was perfor-
med via using only secondary antibodies («Control»).
Working dilution of the anti-peptide antibody prepara-
tion against eEF1A2 is specified in the figure legends.
Pierce® Mouse Anti-Goat IgG («Thermo scientific»)
conjugated to biotin was used as a secondary antibody
with the working dilution 1:250. Ultra-Sensitive ABC
Peroxidase Staining Kit («Thermo scientific») was used
for the visualization of immune complexes with anti-
peptide antibodies.
Commercially available Anti-EF1 antibody prepa-
ration (clone CBP-KK1, «Upstate», USA) with the wor-
king dilution 1:100 was used for the detection of both
eEF1A isoforms. The immune complexes were visuali-
zedwith the help of «UltraVisionQuanto Detection Sys-
temHRP» («Thermo scientific»). Photodocumenta tion
of the immunohistochemistry results was done on «Leica
DM1000» microscope (Germany) using 40 objective.
Immunoblotting of proteins was performed as descri-
bed in [28]. The secondary antibodies (1:5000 dilution)
against goat IgGs conjugated to horseradish peroxi-
dase («Imtek», Russian Federation) were used for de-
tection of primary anti-peptide antibodies. Peroxidase-
conjugated rabbit antibodies against mouse IgGs («Sig-
ma», USA) were used at 1:10,000 dilution in immuno-
blotting with Anti-EF1 (clone CBP-KK1, «Upstate»,
USA). Visualization of immune complexes on the blot-
ting membrane was done using ImmobilonWestern Che-
miluminescent HRP substrate from «Millipore» (USA).
Immunoblotting images were obtained on «ChemiDoc»
(«Bio-Rad Laboratories», USA).
Results and discussion. Characterization of anti-
peptide antibodies against eEF1À2 by immunohistoche-
mistry and immunoblotting. Recently, we have shown
that the immunization of mice with KSDPPQEAAQFT
SQ peptide conjugated to BSA led to the generation of
antibodies that specifically recognized eEF1A2, but not
eEF1A1 [26]. However, mouse immunization did not al-
low obtaining the amount of antibodies sufficient formul-
tiple histochemical trials; hence, a large-scale anti-pep-
tide antibody preparation via goat immunizationwas star-
ted. The same eEF1A2 fragment was used as a peptide
antigen, which was conjugated to hemocyanin (3–6 pep-
tide copies per the hemocyaninmonomer conjugate) and
to ovalbumin (2–5 peptide copies per the conjugate mo-
lecule). The peptide conjugated to hemocyanin led to
the generation of antibodies (Supplementary, Fig. S1)
that recognized the native eEF1A2 (titer 1:2000) better
than the denatured one (titer 1:1000). Further immuniza-
tion with the peptide-ovalbumin conjugate resulted in an
increase of the antibodies titer against denatured eEF1A2
up to 1:2000 (Supplementary, Fig. S2), thus making the
antibody preparation more suitable for immunoblotting
and immunohistochemical experiments. After the affinity
purification, 1 g of affinity-purified peptide-specific
IgG was enough to detect 0.05 g eEF1A2 in ELISA.
Primarily, the specificity of affinity-purified antibo-
dies against eEF1A2was tested using individual eEF1A1
and eEF1A2 proteins. As shown in Fig. 1, A, the anti-
bodies against eEF1A2 did not cross-react with eEF1A1
even at two fold excess of the latter on the membrane.
On the other hand, the commercial antibody against
eEF1A recognizes both isoforms (Fig. 1, B). We fur-
ther tested the anti-peptide antibodies using the extracts
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of normal rabbit tissues that contained different isoforms
of translation elongation factor: muscle and heart, as
eEF1A2 positive tissues, and liver and lung, as eEF1A2
negative tissues. Rabbit tissues were chosen because
both isoforms of eEF1A is 100% identical to the corres-
ponding human proteins. As shown in Fig. 2, anti-
eEF1A2 antibodies recognized 50 kDa band in the ex-
tracts of rabbit muscle and heart, but no signal was ob-
served in the extracts of liver and lung. Thus, the im-
munoblotting analysis of tissue extracts confirmed a
high specificity of the prepared antibodies and valida-
ted their use for the immunohistochemical studies.
Anti-peptide antibodies against eEF1A2 were em-
ployed for the immunohistochemical detection of eEF1A2
in sections of rabbitmuscles, heart, lung and liver (Fig. 3).
The sections of rabbit heart and muscles demonstrated
a strong positive reactivity (intense brown) for eEF1A2.
To the contrary, the lung and liver tissue sections were
not stained after the treatment with the same antibodies.
The control sample treatment with the secondary anti-
bodies only resulted in no staining. When the commer-
cial antibody that recognizes both isoforms of eEF1A
was used, all tissues were positively stained (Supple-
mentary, Fig. S3). Thus, the anti-peptide antibodies
against eEF1A2 specifically recognized this protein at
tissue sections containing eEF1A2, but not eEF1A1
that confirmed their suitability for immunohistoche-
mical studies.
Determination of eEF1A2 in human tumor samples
by immunohistochemistry and immunoblotting. Paraf-
fin sections of postoperative material were employed
for the determination of eEF1A2 in the samples of hu-
man lung and breast tumors by immunohistochemical
analysis with the help of anti-eEF1A2 anti-peptide an-
tibodies. The tumor samples were compared to those of
the normal tissue that surrounded the tumor and consi-
dered as healthy.
Since eEF1A2 protein was previously detected in
breast tumors by immunohistochemistry using the anti-
bodies from another laboratory [8, 18], we decided to
verify this result using our peptide-specific antibodies.
We examined 4 pairs (tumor and normal tissues) of post-
operative samples of the human breast cancer (Fig. 4).
The clusters of big cells with brown cytoplasm and nuc-
lei were observed in the tumor samples (BrCr#). The
morphology of these cells was atypical compared to the
normal lung cells; hence they could be considered as the
cancerous ones. Unexpectedly, the putative normal samp-
les (BrN#) were also stained brown though less inten-
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Fig. 1. The anti-peptide antibodies
recognize the individual eEF1A2,
but not eEF1A1, inWestern blot: A –
the membrane was treated with the
primary anti-peptide antibodies
(0.24 g/l) against eEF1A2; B –
the membrane was treated with
commercial antibody that recog-
nizes both isoforms of eEF1A. M –
prestaind molecular weight pro-
teins markers, kDa («Thermo
scientific»)
15 30 10 20 10 20 10 20 µg
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Fig. 2. The anti-peptide antibodies recognize eEF1A2 protein in the
heart and muscles extracts in the Western blot. Working dilution of the
antibodies was 0.24 g/ml. Time of membrane exposition was 1 min;
M – molecular weight proteins markers, kDa (PageRuller «Thermo-
scientific»)
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Fig. 3. Immunohistochemical stai-
ning of the normal rabbit tissue sec-
tions with the peptide-specific anti-
bodies against eEF1À2. Control
samples were treated with the se-
condary antibodies only. Magnifi-
cation 40. Nuclei were counter-
stained with hematoxilin
BrCr1 Control BrN1 Control
BrCr2 Control BrN2 Control
BrCr4 Control BrN4 Control
BrCr3 Control BrN3 Control
Fig. 4. Immunohistochemical stai-
ning of the human breast tumor
(BrCr#) and normal (BrN#) tissue
sections from different patients with
the antibodies specific to eEF1A2.
Working concentration of antibo-
dies was 1.2g/ml. Control samples
were treated with the secondary an-
tibodies only. Magnification 40
LCr1 Control LN1 Control
LCr3 Control LN3 Control
Fig. 5. Immunohistochemical stai-
ning of the human lung tumor
(LCr#) and normal (LN#) tissue
sections from different patients with
the antibodies specific to eEF1A2.
Working concentration of antibo-
dies was 1.2g/ml. Control samples
were treated with the secondary an-
tibodies only. Magnification 40
sively, whereas the morphology of these tissue samples
differed from the tumorous ones.
However, a small number of cells with the atypical
morphology and intense staining could also be seen in
the samples BrN3 and BrN4.
The same immunohistochemical analyses were per-
formed for the samples (tumor and normal tissues) of hu-
man lung cancer (LCr#). The positive staining was ob-
served in all lung tumor samples in the presence of the
specific antibodies against eEF1A2 (Fig. 5). Clusters of
big cancer cells with brown cytoplasm and nuclei were
clearly seen. Normal tissues surrounding the tumors
(LN#) were also stained brownish despite the cell mor-
phology in these samples was distinctly different from
that in tumor tissues. Consequently, the samples desig-
nated as «breast or lung normal» contained eEF1A2 iso-
form that was detected by the peptide-specific antibodies.
We showed that the anti-peptide antibodies against
eEF1A2 specifically recognized this protein in the cru-
de tissue extracts (Fig. 2). This allowed us to screen tu-
mor extracts (postoperative samples) for the presence of
eEF1A2 by immunoblotting. A strong signal that corres-
ponds to 50 kDa protein was detected in all extracts deri-
ved from tumors and in most extracts, except LN4, of
lung normal tissue (Fig. 6,A). This result confirms the im-
munohistochemical data obtained on samples of human
lung tumor (Fig. 5). It is worth mentioning that in nor-
mal rabbit lung tissue eEF1A2was not detected (Fig. 2).
Thus, the results of immunohistochemical analysis
and immunoblotting confirm the expression of eEF1A2
isoform in certain malignant tumors. It is in accordance
with the previous results obtained for the lung cancer
samples [9, 23].
We also analyzed two pairs (tumor and normal tis-
sue) of protein extracts derived from patients with gast-
ric cancer (Fig. 6, B). Although the signal from eEF1A2
was observed only in one pair of extracts, this protein
was still present in both tumor and normal samples.
Hence, we confirmed the expression of eEF1A2 in
the lung, breast and stomach malignant tumors and res-
pective normal tissues surrounding the tumors. The pre-
sence of eEF1A2 in the normal tissues adjacent to the tu-
mors was somewhat surprising result. Undoubtedly, it
requires further studies on a larger number of samples.
On the one hand, this fact makes eEF1A2 protein a
somewhat compromised tumor marker, on the other
hand, it raises the question about the «normality» of
cells adjacent to the tumor.
It might be of interest to analyze the correlation bet-
ween the presence of eEF1A2 in those tissues, where it
is absent in the normal state, and the stage of their malig-
nant transformation. Since the antipeptide antibodies
against eEF1A2 do not cross-react with eEF1A1, the
positive staining of the normal tissues surrounding the
tumors cannot be simply explained by a non-specific ef-
fect of the antibodies.
It is known that tumors somehow affect their envi-
ronment. Cancer cells can influence a surrounding nor-
mal tissue directly by paracrine factors or indirectly via
stromal cells [29]. It has been shown recently that the
fibroblasts extracted from the tissue in tumor burden zo-
nes, distal normal zones and interface zones between
tumor and normal tissue differed with respect to their
ability to induce the epithelial-mesenchymal MCF7 cell
transition,modulation of themembrane-type 1matrix-me-
talloproteinase expression, activation of the ERK signa-
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Fig. 6. A –Western blot ana-
lysis of the human lung can-
cer (LCr#) and normal tis-
sue (LN#) extracts; B – hu-
man gastric cancer (T#) and
normal tissue (N#) extracts
with the peptide-specific an-
tibodies against eEF1A2.
The working concentration
of the antibodies was 0.24
g/ml. Exposure time was 1
min; M – molecular weight
proteins markers, kDa (Pa-
geRuller «Thermo scien-
tific»)
ling cascade and promotion of the cancer cell migration
[30]. The fibroblasts isolated from the tumor interface
zone exhibited more robust biological modulatory acti-
vity and promoted the breast cancer cell migration. This
suggests that the interface zone of the tumor represents a
dynamic region vital to the tumor progression [30].
The presence of eEF1A2 in the cancer samples of
different tissues has been well documented [18–25],
but the molecular events underlying this phenomenon
are still not understood. We can speculate that the ex-
pression of EEF1A2 gene in the normal tissues surroun-
ding the tumor may be also somehow induced by can-
cer cells. The molecular mechanism of such induction
remains to be investigated.
Conclusions. The anti-peptide antibodies that speci-
fically recognize eEF1A2, but not eEF1A1, were obtai-
ned after goat immunization and affinity chromatogra-
phy purification. These antibodies were used for the de-
termination of eEF1A2 protein in both the crude cell ex-
tracts and the postoperative tumor samples. We confir-
med the presence of this protein in tissue specimens of
human lung, breast and stomach malignant tumors by
immunoblotting and immunohistochemistry. The pre-
sence of eEF1A2 in the samples of normal tissue raises
new questions concerning determination of the tumor
boundaries and its influence on the adjacent tissues.
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ôàêòîðà åëîíãàö³¿ òðàíñëÿö³¿ eEF1A2 òà ¿õíº âèêîðèñòàííÿ
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Ìåòà. Îõàðàêòåðèçóâàòè îñîáëèâîñò³ íîâèõ ïåïòèäîñïåöèô³÷-
íèõ àíòèò³ë ïðîòè äðóãî¿ ³çîôîðìè ôàêòîðà åëîíãàö³¿ òðàíñëÿ-
ö³¿ 1À (eEF1A2). Âèçíà÷èòè ïðèñóòí³ñòü ö³º¿ ³çîôîðìè ó ï³ñëÿîïå-
ðàö³éíèõ çðàçêàõ ïóõëèí ìîëî÷íî¿ çàëîçè, ëåãåí³â, øëóíêó ëþäèíè ³
ïîð³âíÿòè ³ç çðàçêàìè óìîâíî¿ íîðìè â³äïîâ³äíèõ òêàíèí. Ìåòî-
äè. Ñïåöèô³÷í³ñòü àíòèò³ë àíàë³çóâàëè ìåòîäàìè ³ìóíîôåðìåíò-
íîãî àíàë³çó, ³ìóíîáëîòèíãó òà ³ìóíîã³ñòîõ³ì³¿. Iìóíîáëîòèíã òà
iìóíîãiñòîõ³ì³þ âèêîðèñòàíî äëÿ âèçíà÷åííÿ eEF1A2 â çðàçêàõ
ïóõëèí ëþäèíè, à òàêîæ óìîâíî¿ íîðìè. Ðåçóëüòàòè. Âñòàíîâëå-
íî, ùî îòðèìàí³ àíòèò³ëà ïðîòè eEF1A2 ñïåöèô³÷íî ðîçï³çíà-
þòü çàçíà÷åíèé á³ëîê â åêñòðàêòàõ òà íà ã³ñòîëîã³÷íèõ çð³çàõ ³
íå âèÿâëÿþòü ïåðåõðåñíî¿ âçàºìîä³¿ ç ïåðøîþ ³çîôîðìîþ ôàêòî-
ðà åëîíãàö³¿. Âèçíà÷åíî, ùî ôàêòîð eEF1A2 ïðèñóòí³é â ï³ñëÿîïå-
ðàö³éíèõ çðàçêàõ ïóõëèí ìîëî÷íî¿ çàëîçè, ëåãåí³â ³ øëóíêó, à òà-
êîæ â óìîâíî íîðìàëüíèõ çðàçêàõ öèõ òêàíèí. Âèñíîâêè. Íàìè
îäåðæàíî âèñîêîñïåöèô³÷í³ àíòèò³ëà ïðîòè eEF1A2, ÿê³ ìîæíà
âèêîðèñòîâóâàòè â ³ìóíîëîã³÷íèõ äîñë³äæåííÿõ çðàçê³â ïóõëèí.
Êëþ÷îâ³ ñëîâà: eEF1A2, àíòèïåïòèäí³ àíòèò³ëà, ³ìóíîáëî-
òèíã, ³ìóíîã³ñòîõ³ì³ÿ.
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Ì. È. Êîâàëåíêî, Å. Ô. Êîëåñàíîâà, Å. À. Åãîðîâà, À. À. Ìèøèí,
Ì. Ñ. Êðîòåâè÷, Ë. Â. Ñêîðîäà, Á. Ñ. Íåãðóöêèé
Ðåçþìå
Öåëü. Îõàðàêòåðèçîâàòü îñîáåííîñòè íîâûõ ïåïòèäîñïåöèôè-
÷åñêèõ àíòèòåë ïðîòèâ âòîðîé èçîôîðìû ôàêòîðà ýëîíãàöèè
òðàíñëÿöèè 1À (eEF1A2). Îïðåäåëèòü íàëè÷èå ýòîé èçîôîðìû â
ïîñëåîïåðàöèîííûõ îáðàçöàõ îïóõîëåé ìîëî÷íîé æåëåçû, ëåãêèõ,
æåëóäêà ÷åëîâåêà è ñðàâíèòü ñ óñëîâíîé íîðìîé ñîîòâåòñòâóþ-
ùèõ òêàíåé. Ìåòîäû. Ñïåöèôè÷íîñòü àíòèòåë àíàëèçèðîâàëè
ìåòîäàìè èììóíîôåðìåíòíîãî àíàëèçà, èììóíîáëîòèíãà è èì-
ìóíîãèñòîõèìèè. Ìåòîäû èììóíîáëîòòèíãà è èììóíîãèñòîõè-
ìèè èñïîëüçîâàëè äëÿ îïðåäåëåíèÿ eEF1A2 â îáðàçöàõ îïóõîëåé ÷å-
ëîâåêà, à òàêæå óñëîâíîé íîðìû. Ðåçóëüòàòû. Óñòàíîâëåíî, ÷òî
ïîëó÷åííûå àíòèòåëà ïðîòèâ eEF1A2 ñïåöèôè÷åñêè ðàñïîçíàþò
ýòîò áåëîê â ýêñòðàêòàõ è íà ãèñòîëîãè÷åñêèõ ñðåçàõ è íå âûÿâ-
ëÿþò ïåðåêðåñòíîãî âçàèìîäåéñòâèÿ ñ ïåðâîé èçîôîðìîé ôàêòî-
ðà ýëîíãàöèè. Ìû îïðåäåëèëè, ÷òî ôàêòîð eEF1A2 ïðèñóòñòâó-
åò â ïîñëåîïåðàöèîííûõ îáðàçöàõ ìîëî÷íîéæåëåçû, ëåãêèõ èæå-
ëóäêà, à òàêæå â óñëîâíî íîðìàëüíûõ îáðàçöàõ ýòèõ òêàíåé. Âû-
âîäû. Ïîëó÷åííûå íàìè àíòèòåëà ïðîòèâ eEF1A2 ÿâëÿþòñÿ âû-
ñîêîñïåöèôè÷åñêèìè ïî îòíîøåíèþ ê àíòèãåíó è ìîãóò áûòü èñ-
ïîëüçîâàíû â èììóíîëîãè÷åñêèõ èññëåäîâàíèÿõ îïóõîëåé.
Êëþ÷åâûå ñëîâà: eEF1A2, àíòèïåïòèäíûå àíòèòåëà, èììó-
íîáëîòèíã, èììóíîãèñòîõèìèÿ.
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